<DOC>
	<DOCNO>NCT02047461</DOCNO>
	<brief_summary>This study include screen period , 6-month treatment period , 60-month , long-term extension period .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study ALXN1101 Pediatric Patients With MoCD Type A Currently Treated With rcPMP</brief_title>
	<detailed_description>Patients receive daily IV infusion ALXN1101 start Day 1 . After prescribed period , dose increase monthly base define patient safety measure . After Month 6 , patient continue daily dose Month 66 last tolerate dose .</detailed_description>
	<mesh_term>Metal Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Male female patient genetically confirm diagnosis MoCD Type A ( MOCS1 mutation ) Currently treat rcPMP infusion Current plan treatment another investigational drug device , exception rcPMP treatment Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Molybdenum cofactor deficiency ( MoCD )</keyword>
	<keyword>molybdenum cofactor ( MoCo ) biosynthesis</keyword>
	<keyword>sulfite oxidase ( SO )</keyword>
	<keyword>xanthine dehydrogenase</keyword>
	<keyword>aldehyde oxidase</keyword>
	<keyword>S sulfocysteine ( SSC )</keyword>
</DOC>